Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.
You may also be interested in...
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol
Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it